T-Therapeutics Raises $133 Million In Series B Funding To Advance Cancer And Autoimmune Disease Treatments
· pulse2.com · popularity 16/100 · 0 similar stories today · Entrepreneurship & Startups (Business & Finance)
Read the original at pulse2.com →
Summary
T-Therapeutics, a Cambridge, United Kingdom-based biotechnology company developing T cell receptor therapies for cancer and autoimmune diseases, has raised $133 million in an oversubscribed Series B financing round. The investment was co-led by Advent Life Sciences and British Business Bank, with participation from Johnson & Johnson Innovation – JJDC, Samsara BioCapital, M-Ventures, and Eli Lilly and Company. Existing major shareholders Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent, and BGF also participated. The post T-Therapeutics Raises $133 Million In Series B Funding To Advance Cancer And Autoimmune Disease Treatments appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 16.